View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 21, 2018

HKBU unveils new device to enable safe growth of neural stem cells

Researchers from Hong Kong Baptist University (HKBU) have developed a device containing a specific nanotechnology layer to enable the proliferation of neural stem cells (NSCs) in vitro.

Researchers from Hong Kong Baptist University (HKBU) have developed a device containing a specific nanotechnology layer to enable the in vitro proliferation of neural stem cells (NSCs).

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

The research team was jointly led by Department of Biology professor Ken Yung Kin-lam and Department of Physics associate professor Dr Jeffery Huang Zhifeng.

This medical device is expected to help in reducing the risk of carcinogenesis or inflammation in stem cell therapy which is used to treat neurodegenerative, chronic systemic diseases and other degenerative joint diseases.

HKBU has already filed for a US patent for this device.

“The device is expected to help reduce the risk of carcinogenesis or inflammation in stem cell therapy which is used to treat neurodegenerative, chronic systemic and other degenerative joint diseases.”

Professor Ken Yung said: “With the global population ageing rapidly, neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease, are regarded as the main threat and burden to global healthcare.

“Recently, scientists have turned their focus on cell replacement therapies, including stem cell therapy, which have shown huge promise in treating neurodegenerative diseases.

“Stem cell therapy is a treatment using stem cells to cultivate new and normal cells, tissues or organs and then transplanted to people to restore physiological function by replacing damaged or dead cells.”

He added that the conventional methods used to grow and differentiate NSCs need multiple additional growth factors in a culture medium.

These culture mediums are specific forms of polypeptides that can regulate various aspects of cellular function, which in turn can encourage cancer cells growth or increase the risk of tumours in vivo following transplantation.

Composed of biocompatible materials, the layer of nanostructure in the new medical device prevents the use of additional growth factors for cultivating cells.

HKBU expects that following proliferation and cell differentiation, the mature cell can become a therapeutic agent for stem cell therapy.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network